ClinicalTrials.gg
CompletedNCT03564938Updated Dec 3, 2024

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

A Phase 4 interventional study of Regorafenib (Stivarga, BAY73-4506) in Metastatic Colorectal Cancer, sponsored by Bayer. Completed at 13 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Enrollment
20th of 58
100 · median 55
Started
2018
with 3 others
Phase 4
3 of 59
none open now
Registered
30th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 20th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 in phase 4, and was the 30th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously treated with fluoropyrimidine , oxaliplatin-, and irinotecan based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • mCRC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients (≥18 years of age) with (Stage IV) colorectal adenocarcinoma confirmed either histologically or cytologically, with measurable metastatic disease according to v. 1.1
  • Patients must have PD after receiving the approved standard therapies
  • Patients must have PS of 0 or 1 and a of at least 3 months
  • Adequate bone marrow, liver and renal function
  • Women of and men must agree to use adequate

Exclusion criteria

Exclusion Criteria:

  • Unresolved toxicity greater than Grade 1 from prior treatment for mCRC
  • Previous (within 28 days) or concomitant participation in another clinical study with medicinal product(s)
  • Subjects unable to swallow oral medications
  • Any malabsorption condition
  • Any medical or surgical conditions within 28 days before start of regorafenib that will interfere with patient's participation in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Regorafenib (Stivarga, BAY 73-4506)

    Patients with metastatic colorectal cancer

    Drug: Regorafenib (Stivarga, BAY73-4506)

Interventions

  • The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).

    Also known as: Nublexa

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    Time frame: From the start of regorafenib treatment up to 30 days after the last dose of regorafenib

  2. Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS)

    Time frame: From the start of regorafenib treatment up to 30 days after the last dose of regorafenib

  3. Percentage of participants with change in worst grades for hematological and biochemical toxicities according to CTCAE version 4.03, based on laboratory measurements

    Time frame: From the start of regorafenib treatment up to 30 days after the last dose of regorafenib

  4. Change in Body weight (kg)

    Time frame: From the start of regorafenib treatment up to 30 days after the last dose of regorafenib

  5. Change in Body height (cm)

    Time frame: From the start of regorafenib treatment up to 30 days after the last dose of regorafenib

  6. Change in Systolic / Diastolic BP (mmHg)

    Time frame: From the start of regorafenib treatment up to 30 days after the last dose of regorafenib

  7. Change in heart rate (beats/min)

    Time frame: From the start of regorafenib treatment up to 30 days after the last dose of regorafenib

Secondary outcomes

  1. Disease control rate (DCR)

    Defined as proportion of patients achieving complete response (CR), partial response (PR), or SD (stable disease) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1

    Time frame: In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first

  2. Overall response rate (ORR)

    Defined as proportion of patients achieving CR, and PR per RECIST v.1.1

    Time frame: In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first

  3. Progression free survival (PFS)

    Progression free survival is defined as the time from study drug assignment to progressive disease (PD) or death from any cause or date of last tumor assessment if the patient did not progress or die.

    Time frame: In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first

  4. Overall survival (OS)

    Overall survival is defined as the time from study drug assignment to death from any cause or last date when the patient was known to be alive.

    Time frame: In each participant, every 8 weeks from the start of regorafenib until death, lost to follow-up, consent withdrawn or end of study, whichever occurs first

07

Study locations

13 sites
  • Apollo Research Foundation
    Hyderabad, Andhra Pradesh 500096, India
  • Sir Ganga Ram Hospital
    New-Delhi, Delhi 110060, India
  • Shalby Hospital
    Ahmedabad, Gujarat 380054, India
  • Healthcare Center Global Hospital
    Ahmedabad, Gujarat 380060, India
  • Tata Memorial Hospital
    Mumbai,, Maharashtra 400012, India
  • Jaslok Hospital and Research Centre
    Mumbai, Maharashtra 400026, India
  • Sushrut Hospital & Research Centre
    Mumbai, Maharashtra 400071, India
  • Jehangir Hospital
    Pune, Maharashtra 411001, India
  • Fortis Hospital
    West-Mumbai, Maharashtra 400078, India
  • Sparsh Hospital & Critical Care
    Bhubaneswar, Orissa 751007, India
  • Apollo Speciality Hospitals
    Madurai, Tamil Nadu 625020, India
  • IPGME & R / SSKM Hospital
    Kolkata, West Bengal 700020, India
  • Health Point Hospital
    Kolkata, West Bengal 700025, India
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Mar 2023, 55 months.

Of 38 phase 4 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 57. This study's 55 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2018
First posted
Jun 21, 2018
StartActual
Jul 30, 2018
Primary completionActual
Mar 20, 2023
CompletionActual
Dec 1, 2023
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03564938
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 21, 2018
Start date
Jul 30, 2018
Primary completion
Mar 20, 2023
Completion
Dec 1, 2023
Last update
Dec 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion